Approval Date - 23rd February 2018

The Board:

1. Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 to GF/B38/EDP12 (“Table 1”);

2. Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;

3. Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and

4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

This decision does not have material budgetary implications for operating expenses.

Table 1: Secretariat’s Funding Recommendation on Funding from the 2017-2019 Allocation: Please note that the country name is linked to the extranet site where supporting documents are available for review

<table>
<thead>
<tr>
<th>N</th>
<th>Applicant</th>
<th>Disease component</th>
<th>Proposed Principal Recipient</th>
<th>Grant name&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Grant end date</th>
<th>Currency</th>
<th>Total program budget</th>
<th>Catalytic funds in grant</th>
<th>Domestic commitment&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Unfunded quality demand</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Guinea</td>
<td>HIV</td>
<td>The Ministry of Public Health of the Republic of Guinea</td>
<td>GIN-H-MOH</td>
<td>31/12/2020</td>
<td>US$</td>
<td>33,573,749</td>
<td>N/A</td>
<td>(previously reported)</td>
<td>N/A</td>
</tr>
</tbody>
</table>

<sup>a</sup> Grant name is subject to change based on the ISO code.

<sup>b</sup> Domestic commitments pertain to the disease programs and exclude other specific commitments for RSSH, unless otherwise specified. Commitments for disease specific programs and RSSH are subject to local currency value fluctuation against US dollar and Euro currencies.